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http://www.biomedcentral.com/1472-6963/12/147RESEARCH ARTICLE Open AccessHealth coaching by telephony to support
self-care in chronic diseases: clinical outcomes
from The TERVA randomized controlled trial
Kristiina Patja1*, Pilvikki Absetz1, Anssi Auvinen2, Kari Tokola2, Janne Kytö3, Erja Oksman4, Risto Kuronen4,
Timo Ovaska3, Kari Harno5, Mikko Nenonen6, Tom Wiklund3, Raimo Kettunen4 and Martti Talja4Abstract
Background: The aim was to evaluate the effect of a 12-month individualized health coaching intervention by
telephony on clinical outcomes.
Methods: An open-label cluster-randomized parallel groups trial. Pre- and post-intervention anthropometric and
blood pressure measurements by trained nurses, laboratory measures from electronic medical records (EMR). A total
of 2594 patients filling inclusion criteria (age 45 years or older, with type 2 diabetes, coronary artery disease or
congestive heart failure, and unmet treatment goals) were identified from EMRs, and 1535 patients (59%) gave
consent and were randomized into intervention or control arm. Final analysis included 1221 (80%) participants with
data on primary end-points both at entry and at end. Primary outcomes were systolic and diastolic blood pressure,
serum total and LDL cholesterol concentration, waist circumference for all patients, glycated hemoglobin (HbA1c)
for diabetics and NYHA class in patients with congestive heart failure. The target effect was defined as a
10-percentage point increase in the proportion of patients reaching the treatment goal in the intervention arm.
Results: The proportion of patients with diastolic blood pressure initially above the target level decreasing to
85 mmHg or lower was 48% in the intervention arm and 37% in the control arm (difference 10.8%, 95% confidence
interval 1.5–19.7%). No significant differences emerged between the arms in the other primary end-points.
However, the target levels of systolic blood pressure and waist circumference were reached non-significantly more
frequently in the intervention arm.
Conclusions: Individualized health coaching by telephony, as implemented in the trial was unable to achieve
majority of the disease management clinical measures. To provide substantial benefits, interventions may need to
be more intensive, target specific sub-groups, and/or to be fully integrated into local health care.
Trial registration: ClinicalTrials.gov Identifier: NCT00552903Background
Diabetes and cardiovascular diseases represent large and
costly chronic healthcare challenges [1]. Preventative
measures can effectively reduce costs [2]. Despite differ-
ences between different conditions, the expectations on
the patients are similar: to cope with multiple medica-
tions and co-morbidities, to alter behavior, to deal with
social and psychological impacts of symptoms and to
interact with medical care [3,4].* Correspondence: Kristiina.patja@promedico.fi
1National Institute of Health and Welfare, Helsinki, Finland
Full list of author information is available at the end of the article
© 2012 Patja et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orHealth care providers have a difficult task in trying to
manage chronic disease care in complex service systems
that are poorly designed to motivate, equip and em-
power patients to behavior changes [5-7]. Resources
should aim at maximized health gains, and this requires
reorientation of services [8]. High expectations are put
on information technology solutions that have been
shown highly effective in promoting lifestyle changes [9].
So far, comprehensive efforts to assess the impact of in-
corporating a range of IT tools in chronic disease man-
agement have been targeting single disease groups, such
as CHD [10,11], heart failure [12] or diabetes [13,14]d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Eligibility and exclusion criteria of TERVA trial
Eligibility criteria for enrollment included:
1. Residents in the region of Päijät-Häme aged 45 years or older
2. One of the following diagnose
a. Heart failure with NYHA II or III, and a history of hospital
admission for heart failure within the last 2 years
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groups and/or co-morbidities are lacking.
While technology can be an effective way to improve
reach of disease management interventions, still the con-
tent is more important. Health coaching, a collaborative
process characterized by motivational communication,
patient-defined goals related to disease management,
and patient acceptance of accountability for decisions
made [15] can utilize different sets of self-management
tools (SMTs) to promote adoption of an active role in
self-care by the patient [16]. Health coaching can im-
prove quality, effectiveness and cost-effectiveness of dis-
ease management [17]. The TERVA trial is the first large
randomized controlled trial to simultaneously evaluate
tele-coaching in a real-world health care setting in three
patient groups: congestive heart failure (CHF), coronary
artery disease (CAD) and type 2 diabetes mellitus (T2D).
The aim of the trial was to assess the effect of health
coaching on clinical outcomes (risk determinants) after
one-year intervention.
Methods
Trial design
The TERVA study is a randomized, open-label, parallel
groups trial comparing health coaching and usual care.
The primary end points were defined as 10-percentage
point difference between arms in increase in the propor-
tion of participants reaching the target level in five glo-
bal and two patient-group specific clinical parameters at
12 months (Table 1). The targets were set in accordance
with Finnish evidence-based guidelines.
Measures
Research nurses, unaware of the allocation, measured
blood pressure and waist circumference in both arms.
The laboratory results were extracted from the elec-
tronic medical records (EMR) at both entry and end of
the intervention (at entry between 3 months before to
1 month after and at end 11 to 15 months from date ofTable 1 Primary and secondary end points of TERVA trial
Primary end points
▪ Provider-measured BP ≤140/85 mmHg
▪ Total cholesterol ≤4.5 mmol/L
▪ LDL ≤2.5 mmol/L
▪ Waist circumference ≤94 cm for men and ≤80 cm for women – later
revised as 90 cm for women and 100 cm for men based on national
guidelines
For congestive heart failure an additional end-point:
▪ Improved or maintained NYHA class
For participants with T2D:
▪ HbA1c ≤7%consent). NYHA-class was obtained from study ques-
tionnaires at entry and end of follow-up.Identification and enrollment
Patients were enrolled from Päijät-Häme in the Southern
Finland, a region with a population of 212,000. The tar-
get population was initially identified from primary care
and hospital registries and records, followed by a
detailed assessment of medical records (Table 2).
Patients with more than one condition were enrolled in
the following hierarchy: CHF - CAD - T2D, so CHF
patients could have CAD and/or T2D, but not the other
way around. All eligible patients were sent an informa-
tion letter and a consent form in four batches during a
12-month period in 2007–2008 with one reminder for
non-responders followed by a telephone call. Of the
2594 eligible patients 59.2% (1535) gave consent and
were invited for an examination and interview by the re-
search nurse, and 1225 (79.8%) completed it. The final
analysis included 1221 patients (80%) having data on pri-
mary end-points both at entry and at end of follow-up.
1215 had both baseline and end of study measurements
of waist circumference and blood pressure available (812
or 87% of committed patients in the intervention arm
and 403 or 87% in the control arm). Laboratory mea-
sures of lipids at both time points were available in
EMRs only for a fifth of the patients, and HbA1c for 54%
of the patients with diabetes. The age and sex distribu-
tion of the drop-outs did not differ from the analyzed
patients (mean ages 65.0 vs. 64.8 years, 60.6% vs. 58.1%
men). There were no substantial differences betweenb. History of myocardial infarction or cardiac revascularization
procedure, and one of the following (treated or untreated):
blood pressure above 140/85 mmHg, total serum
cholesterol concentration
>4.5 mmol/L, serum LDL concentration >2.5 mmol/L
c T2D on medication and serum HbA1c >7% without clinically
evident cardiovascular diseases e.g. MI, stroke, peripheral
vascular disease
Exclusion criteria:
● Inability to cooperate or participate
● Pregnancy
● Life expectancy less than 1 year
● Patients with major elective surgery planned within 6 months
● Patient has had major surgery within the last 2 months
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baseline.
Randomization
A cluster design was used to accommodate the effects of
individual health coaches with multiple patients. The
randomization algorithm was based on computer-gener-
ated random numbers. A stratified randomization with
permuted blocks was used to ensure balanced distribu-
tion within disease group and municipality between the
arms. A Zelen type randomization (2:1 ratio for inter-
vention/control arm) was performed prior to consent
(Figure 1).
Intervention
Health coaching was delivered from November 2007 by
seven experienced certified nurses or public health
nurses. They were trained for four weeks in a tele-coach-
ing model initially developed by Pfizer Health Solutions2594 eligil
patients 
randomi
Analysed (n=816) 
Lost to follow-up (no information) 
(n=10) 
Discontinued intervention (quit or 
drop out) (n=106) 
withdraw consent (n=23) 
dead (n=17) 
other reason (n=66) (e.g. 
moved to other area, serious 
illness)
Allocated to intervention arm 
(n=1034) 
Committed to intervention 
and usual care (n=932) 
No commitment (n=102)
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Follow
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Figure 1 Flow Diagram. Distribution of study population from those fillin
intervention.(PHS) but modified for the Finnish health care system.
Patients in the intervention group were called monthly,
altogether 10–11 times. After a brief engagement call,
there was one broader needs assessment call, followed
by monthly coaching calls and finally an evaluation call.
In between the coaching calls there was an opportunity
for brief follow-up calls, but these were rarely used. The
coaching call topics were based on 8 key recommenda-
tions of the program, with variations due to individual
patient’s preferences (Figure 2). The behavior change
component integrated behavior change techniques from
the Self-Regulation Theory and supported by evidence,
i.e., self-monitoring, goal setting, action planning, and
feedback [18]. After the first two months, quality assur-
ance measures were taken in the form of listening to
randomly selected 2–3 calls from each coach. Call length
was also monitored. Calls were found to be long, typic-
ally up to 60 min, and they were based on a coach
driven information provision model, and very littleibility 
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Figure 2 Pfizer Health Solutions has developed a tele-coaching intervention with 5 key functions and 8 recommendations to engage,
inform, involve, and empower the patients in self-care.
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improve quality, an explicit structure following the self-
regulation model was developed jointly with the coa-
ches, and the maximum number of topics to be tackled
during one call, was limited to three. Also, coaches
were further trained in Motivational Interviewing tech-
niques of active listening, and using open questions, re-
flection and summaries [19], and they all received two
individual supervision sessions in self-monitoring and
developing their coaching practices. With these mea-
sures, quality (defined as use of structure and Motiv-
ational Interviewing techniques, and concrete actions as
outcomes of the calls) was improved while call length
decreased to approximately 30 min. Self-care books
prepared in collaboration with the Finnish Heart Asso-
ciation and the Finnish Diabetes Associations supported
the coaching, and the coach had access to the patients’
EMRs. Both trial arms continued to receive routine
care.
Statistical methods
A sample size of 1250 patients was calculated to provide
adequate statistical power (1-β ≥ 0.8) for detecting a 10
percentage point difference between the intervention
arms (with 6 coaches) with conservative assumptions(α= 0.05 two-sided, 50% of the patients in the control
arm would reach target, a 10% drop out rate and 10%
of the subjects not evaluable at the end of the trial), as
long as the intracluster correlation did not exceed 0.01
[20].
Data analyses were conducted using multilevel meth-
ods (generalized linear mixed models) to account for
the clustered design. The trial data had a two-level
structure, where the health coaches constituted an
upper level, within which the individual patients were
distributed allowing for correlation at individual level
within a cluster (variance components at the two
levels).
A modified intention to treat analyses by trial arm was
employed including all patients with data at entry and at
the end of the 12-month follow-up. No substantial im-
balance at baseline was found in the primary end-point
variables between the arms (Table 3).
Ethical approval and trial number
Written informed consent was obtained from all partici-
pants prior to enrollment into the project. The study
protocol was approved by the Ethics Committee of the
PHSSHD and registered (ClinicalTrials.gov Identifier:
NCT00552903).
Table 3 Baseline data available from patients who were allocated to the study (intervention= 1034, control = 501)
Type 2 Diabetes Coronary artery disease Congestive heart failure
Intervention Control Intervention Control Intervention Control
Number of patients 770 359 172 97 92 45
Age (years) 64.6 (9.4) 65.6 (9.5) 65.4 (9.4) 66.0 (8.6) 67.3 (7.9) 62.4 (7.7)
Sex (% male) 58.3 54.0 69.2 73.2 65.2 64.4
Age at self reported year
of diagnosis
54.3 (11.1) 56.1 (11.8) 60.8 (10.2) 61.3 (10.1) 63.9 (7.9) 56.8 (9.3)
311 145 121 69 51 25
Self-reported duration of disease 10.3 (8.4) 9.2 (8.2) 4.7 (6.6) 4.8 (7.6) 4.4 (5.4) 4.2 (3.7)
302 142 120 68 51 25
Body mass index 32.3 (6.2) 31.9 (5.7) 28.3 (4.1) 28.8 (5.1) 30.2 (6.6) 29.9 (6.9)
727 338 164 91 81 42
Waist circumference (M/F) 109.9 (14.4)/ 106.8
(15.5)
110.1 (12.8)/ 104.8
(15.1)
100.3 (11.0)/ 95.1
(12.8)
102.9 (11.7)/ 91.5
(12.6)
106.7 (12.8)/ 94.1
(14.6)
108.0 (17.9)/ 89.6
(17.3)
429/298 182/156 116/47 66/25 55/25 25/16
Systolic blood pressure (mmHg) 143.4 (20.0) 143.1 (20.2) 137.6 (20.5) 139.9 (18.2) 132.9 (23.7) 127.6 (22.7)
727 337 163 91 81 42
Diastolic blood pressure (mmHg) 84.2 (11.1) 84.1 (10.8) 81.0 (12.2) 82.1 (10.5) 81.3 (14.1) 80.2 (11.5)
727 338 163 91 81 42
Serum total cholesterol (mmol/l) 4.4 (1.1) 4.4 (0.9) 3.8 (0.9) 3.8 (1.0) 4.0 (1.2) 4.0 (1.4)
225 121 66 46 23 12
Serum HDL cholesterol (mmol/l) 1.2 (0.4) 1.3 (0.4) 1.4 (0.4) 1.3 (0.4) 1.1 (0.4) 1.3 (0.5)
219 119 65 45 23 11
Serum LDL cholesterol (mmol/l) 2.3 (0.8) 2.4 (0.8) 1.9 (0.6) 1.9 (0.7) 2.1 (0.9) 2.2 (0.9)
210 115 65 45 21 11
Lipid lowering medication (%) 24.7 20.3 60.5 55.7 38.0 22.2
190 73 104 54 35 10
Daily smokers (%) 12.7 11.0 11.9 10.1 12.7 12.2
88/691 36/327 19/160 9/89 10/79 5/41
Hb1Ac (%) 7.5 (1.1) 7.7 (1.7)
415 224
Oral antidiabetic drug and
insulin (%)
12.3 13.1
95 47
Oral antidiabetic drug (%) 34.0 29.8
262 107
Insulin (%) 16.8 16.7
129 60
SCORE1 8.0 (6.3) 7.6 (7.9)
215 115
NYHA2 2.4 (1.4) 2.5 (1.4)
52 30
1 Score index includes: Sex, Age, Total Chol, HDL and BP, smoking status.
2 New York Heart Association index on angina pectoris.
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In the intervention arm, 48.1% of the patients (156/324)
initially above the target level of diastolic blood pressure
of 85 mmHg reached this value, while for the controlarm the proportion was 37.3% (62/166). The 10.8% (95%
confidence interval (CI) 1.5–19.7%) difference in propor-
tion of patients who reached the goal was statistically
significant and gave a number needed to treat of 10 (CI
Table 4 Proportion (%) of those patients reaching targets in primary end points among those exceeding these values
at baseline in the analysed population (intervention =816, controls = 405)
Type 2 Diabetes Coronary artery disease Congestive heart failure
Intervention Control Intervention Control Intervention Control
Hb1Ac (<7%) 30.2% (n=65/215) 29.7% (n=27/91)
Waist circumference
(<90cm women,
<100cm men)
9.8% (n=46/470) 5.1% (n=12/234) 11.1% (n=8/72) 9.5% (n=4/42) 10.8% (n=4/37) 15.8% (n=3/19)
Systolic blood pressure
(<140mmHg)
32.7% (n=107/327) 35.8% (n=53/148) 47.1% (n=24/51) 16.1% (n=5/31) 60.0% (n=12/20) 0% (n=0/8)
Diastolic blood pressure
(<85mmHg)
45.5% (n=120/264) 37.7% (n=49/130) 56.4% (n=22/39) 26.1% (n=6/23) 66.7% (n=14/21) 53.8% (n=7/13)
Serum total cholesterol
(<4.5mmol/l)
30.7% (n=23/75) 35.0% (n=7/20) 77.8% (n=7/9) 100% (n=3/3) 100% (n=1/1) 0% (n=0/1)
Serum LDL cholesterol
(<2.5mmol/l)
43.4% (n=29/67) 47.4% (n=9/19) 75.0% (n=6/8) 100% (n=2/2) 100% (n=1/1) (n=0)
NYHA class (similar or
improved)
83.9% (n=26/31) 93.3% (n=14/15)
Target reached in at least
one primary endpoint*
47.8% (n=276/578) 44.8% (n=125/279) 49.5% (n=55/111) 43.8% (n=28/64) 75.5% (n=40/53) 65.4% (n=17/26)
*Intervention: 50.0% (371/742), Control: 46.1% (170/369), p= 0.217.
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above the target level of 140 mmHg at baseline, 35.9%
(143/398) in the intervention arm and 31.0% (58/187) in
the control arm reached the target (p= 0.24).
For waist circumference, the target was below 100 cm
for men and 90 cm for women. The difference was not
statistically significant (p= 0.08 combined, 0.07 for males
and 0.65 for females) (Table 4). For patients with T2D,
the goal for HbA1c there was no difference between
intervention and control group (Table 4).
The goal for total cholesterol reduction was reached
more often in control arm than in intervention arm
(p= 0.64) as was the LDL cholesterol target (≤2.5 mmol/
l) (p= 0.68). For patients with CHF, NYHA class
remained similar or improved in both arms (p= 0.39).
The proportion of patients achieving at least one of the
defined primary objectives was 50.0% (371/742) in the
intervention and 46.1% in the control arm (170/369,
p= 0.22). Within the intervention arm, no substantial
differences were found between subjects assigned to dif-
ferent nurses (intracluster correlation 0.01).
Discussion
The TERVA trial was carried out in a real life setting
and aimed at increasing the proportion of intervention
patients reaching at least one of the predefined targets
(blood pressure, HbA1c, waist circumference, NYHA
class or total cholesterol) by 10% compared to controls.
There was a small, non-significant improvement in the
proportion of patients who reached at least one of the
primary endpoints for both the whole study population,
and for each of the disease area subgroups separately.However, the difference reached the predefined 10% dif-
ference between the groups only for the CHF patients.
An encouraging finding is the high adherence, nearly
90% of the patients remained in the trial during the
intervention (similar to the control arm). Further ana-
lysis of the intervention arm will define how well
patients could achieve the goals that they actually set at
the beginning of the intervention.
Chronic disease management is a complex process ur-
ging multiple simultaneous changes in self-care, in
health behavior, and in the interaction with medical care
[3,21]. A complex intervention such as ours that targets
these multiple behaviors cannot be compared to single-
behavior interventions such as smoking cessation, medi-
cation adherence, or physical activity interventions. Des-
pite these methodological complexities, little differences
were found between subjects assigned to different
nurses, indicating consistency in delivering the interven-
tion. Further, health behavior changes may have a
delayed impact or may impact the risk of cardiovascular
diseases independently of clinical outcomes [19]. These
reasons may partly explain that we did not meet our
study objectives. Another possibility is that the intensity
of the intervention was too low to sufficiently cover
multiple behaviors, as recent evidence suggests that tel-
ephony interventions targeting only physical activity or/
and diet produce most favorable effects when the num-
ber of calls is 12 or more [9]. Several previous studies
have assessed the effect of telephony interventions on
similar outcomes as ours [6,7,14,22]. Also these trials
have shown modest improvement in clinical and health
behavior outcomes.
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the public health care system and occupationally active
patients were underrepresented, as they are mostly cov-
ered by occupational health services [23], and retired
patients with more severe disease are overrepresented.
The T2D patients in the trial (selected based on HbA1c
>7% within 6 months prior to inclusion) represented
approximately one third of the T2D patients in the re-
gion [24,25]. Of them 28% had HbA1c >7% at the start
of the intervention, which is comparable to the popula-
tion-based studies of T2D patients [24], suggesting that
the participants are representative of the target popula-
tion. Davidson concluded in his review the key success
factor in diabetes care being specially trained nurses or
pharmacists and perhaps one reason for modest results
was that those in treatment were receiving already spe-
cialist nurse care [4] and added value of telephony was
limited.
We included three different disease areas with vari-
able disease severity. The mean HbA1c was only 7.5% in
intervention arm and 7.7% in control arm, with 28%
and 25% with baseline HbA1c >7 respectively, and dis-
ease history of 9.2 and 10.3 years. The large proportion
of T2D patients with HbA1c at the target level at en-
rollment was due to the fact that the patients were ori-
ginally screened from primary care EMRs, and had
frequently improved by the time of enrollment, which
could be up to 6 months later. Also, the end of study
HbA1c measurement could potentially be up to
10 months after the intervention. The abstraction of
the laboratory data from EMRs instead of a strict meas-
urement protocol was motivated by the pragmatic na-
ture of the trial, but in the low proportion of subjects
with such data at the end of the study reduced the
power (despite reaching the target sample size) and
could introduce bias, as assessments were not pre-
scribed randomly. This limitation renders the findings
related to laboratory data difficult interpret meaning-
fully. Further, the targets for primary end-points, for in-
stance waist circumference, which were based on
systematic reviews of behavioral risk factor and disease
management interventions, may have been too stringent
[26]. Finally, the intervention was not coordinated with
other health care providers, but rather added on top of
the existing services. Some specialist diabetes nurses
expressed a concern that health coaching was challen-
ging their professional role, but no assessments were
carried out to objectively measure health professionals’
perceptions of the coaching program. Therefore, we can
only speculate on the effect of the perceived competi-
tion on the results. However, it should be emphasized
that the changes that were detected under these cir-
cumstances, demonstrate effects achieved in a real life
setting.Conclusions
The results of this trial are inconclusive, as we did meet
the primary end-point for diastolic blood pressure only
with non-significant improvement in systolic blood pres-
sure and waist circumference and no improvement in
glycemic control, cholesterol or NYHA class. The overall
lack of efficacy of health coaching may be related to the
target population, coaching procedures and the duration
of the follow-up time, and will be further explored in
longer follow-up and sub-group analyses, as well as ana-
lysis of behavioral outcomes. Methodological factors and
too strict primary targets may contribute to inability to
meet all the predetermined primary objectives. Further,
the primary analysis focused on efficacy, and analysis on
resource utilization and cost-efficacy need to be per-
formed to fully clarify the role of health coaching by
telephone in this setting.
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